File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.apsb.2020.05.011
- Scopus: eid_2-s2.0-85093948471
- PMID: 33304788
- WOS: WOS:000595499500014
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Injectable thermo-responsive nano-hydrogel loading triptolide for the anti-breast cancer enhancement via localized treatment based on “two strikes” effects
Title | Injectable thermo-responsive nano-hydrogel loading triptolide for the anti-breast cancer enhancement via localized treatment based on “two strikes” effects |
---|---|
Authors | |
Keywords | Thermo-responsive hydrogel Triptolide Tumor local treatment Breast cancer Anti-angiogenesis |
Issue Date | 2020 |
Publisher | Elsevier, published in association with Institute of Materia Medica and Chinese Pharmaceutical Association. The Journal's web site is located at http://www.journals.elsevier.com/acta-pharmaceutica-sinica-b |
Citation | Acta Pharmaceutica Sinica B, 2020, v. 10, p. 2227-2245 How to Cite? |
Abstract | The clinical application of triptolide (TPL) in tumor therapy has been greatly limited by its toxicity and inefficient delivery. Herein, a localized and sustained-release thermo-sensitive hydrogel was developed for the intra-tumor administration of TPL. Based on the amphiphilic structure of poly (N-isopropylacrylamide-co-acrylic acid)-g-F68 copolymer, it was able to form nano-micelles to efficiently encapsulate TPL, and then turn into a hydrogel at 37 °C. TPL@nano-gel exhibited a sustained drug release profile in vitro and a stronger anticancer effect caused by “two strikes”. The “first strike” was its enhanced cytotoxicity compared to free TPL, due to the enhanced pro-apoptosis effect observed in both MDA-MB-231 and MCF-7 cells caused by the regulation of endogenous mitochondrial pathways. Furthermore, TPL@nano-gel exhibited a “second-strike” through its anti-angiogenesis capabilities mediated through VEGFR-2 signaling inhibition. As expected, after intra-tumoral injection at a 0.45 mg/kg TPL-equivalent dose three times over 14 days in 4T1 tumor-bearing mice, TPL@nano-gel led to lower systemic toxicity and higher antitumor efficacy compared to multiple injections of TPL. In this regard, these findings indicate that this injectable thermo-responsive hydrogel carries great potential for TPL as a safe and effective cancer therapy. |
Persistent Identifier | http://hdl.handle.net/10722/294818 |
ISSN | 2023 Impact Factor: 14.7 2023 SCImago Journal Rankings: 3.035 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Luo, Y | - |
dc.contributor.author | Li, J | - |
dc.contributor.author | Hu, Y | - |
dc.contributor.author | Gao, F | - |
dc.contributor.author | Leung, GPH | - |
dc.contributor.author | Geng, F | - |
dc.contributor.author | Fu, C | - |
dc.contributor.author | Zhang, J | - |
dc.date.accessioned | 2020-12-21T11:49:00Z | - |
dc.date.available | 2020-12-21T11:49:00Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Acta Pharmaceutica Sinica B, 2020, v. 10, p. 2227-2245 | - |
dc.identifier.issn | 2211-3835 | - |
dc.identifier.uri | http://hdl.handle.net/10722/294818 | - |
dc.description.abstract | The clinical application of triptolide (TPL) in tumor therapy has been greatly limited by its toxicity and inefficient delivery. Herein, a localized and sustained-release thermo-sensitive hydrogel was developed for the intra-tumor administration of TPL. Based on the amphiphilic structure of poly (N-isopropylacrylamide-co-acrylic acid)-g-F68 copolymer, it was able to form nano-micelles to efficiently encapsulate TPL, and then turn into a hydrogel at 37 °C. TPL@nano-gel exhibited a sustained drug release profile in vitro and a stronger anticancer effect caused by “two strikes”. The “first strike” was its enhanced cytotoxicity compared to free TPL, due to the enhanced pro-apoptosis effect observed in both MDA-MB-231 and MCF-7 cells caused by the regulation of endogenous mitochondrial pathways. Furthermore, TPL@nano-gel exhibited a “second-strike” through its anti-angiogenesis capabilities mediated through VEGFR-2 signaling inhibition. As expected, after intra-tumoral injection at a 0.45 mg/kg TPL-equivalent dose three times over 14 days in 4T1 tumor-bearing mice, TPL@nano-gel led to lower systemic toxicity and higher antitumor efficacy compared to multiple injections of TPL. In this regard, these findings indicate that this injectable thermo-responsive hydrogel carries great potential for TPL as a safe and effective cancer therapy. | - |
dc.language | eng | - |
dc.publisher | Elsevier, published in association with Institute of Materia Medica and Chinese Pharmaceutical Association. The Journal's web site is located at http://www.journals.elsevier.com/acta-pharmaceutica-sinica-b | - |
dc.relation.ispartof | Acta Pharmaceutica Sinica B | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Thermo-responsive hydrogel | - |
dc.subject | Triptolide | - |
dc.subject | Tumor local treatment | - |
dc.subject | Breast cancer | - |
dc.subject | Anti-angiogenesis | - |
dc.title | Injectable thermo-responsive nano-hydrogel loading triptolide for the anti-breast cancer enhancement via localized treatment based on “two strikes” effects | - |
dc.type | Article | - |
dc.identifier.email | Li, J: kimli07@hku.hk | - |
dc.identifier.email | Leung, GPH: gphleung@hkucc.hku.hk | - |
dc.identifier.authority | Leung, GPH=rp00234 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1016/j.apsb.2020.05.011 | - |
dc.identifier.pmid | 33304788 | - |
dc.identifier.pmcid | PMC7715064 | - |
dc.identifier.scopus | eid_2-s2.0-85093948471 | - |
dc.identifier.hkuros | 320686 | - |
dc.identifier.volume | 10 | - |
dc.identifier.spage | 2227 | - |
dc.identifier.epage | 2245 | - |
dc.identifier.isi | WOS:000595499500014 | - |
dc.publisher.place | China | - |